Physician profile
Michael A Derosa
NPI 1770589194
$12,864.62
in general payments reported to CMS, 2019-2025
50 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $696 · 2021: $1,652 · 2022: $2,123 · 2023: $2,196 · 2024: $2,113 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,614 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,614.26 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,080.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,834.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,007.77 | 2019-2025 | Synthroid, Botox |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.76 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $798.21 | 2022-2025 | |
| Abbott Laboratories | $651.98 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $643.73 | 2019-2024 | Korlym |
| Dexcom, INC. | $640.74 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $468.88 | 2019-2023 | Farxiga |
| Antares Pharma, INC. | $380.88 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $339.98 | 2019-2025 | Unithroid |
| Amgen INC. | $307.12 | 2019-2025 | Repatha, Tepezza, Repatha |
| Sanofi-Aventis U.S. LLC | $290.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $278.39 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $277.89 | 2022-2025 | Gvoke Hypopen, Recorlev |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $186.96 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $174.11 | 2021-2025 | Minimed 780g, Simplera Sensor, Intellis Adaptivestim |
| Amarin Pharma, INC. | $173.37 | 2019-2021 | |
| Insulet Corporation | $158.71 | 2019-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $131.51 | 2021-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $129.15 | 2019-2024 | Tirosint, Licart, Licart |
| Mannkind Corporation | $103.38 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $95.44 | 2025 | Yorvipath |
| Clarus Therapeutics INC. | $67.23 | 2021 | |
| Verity Pharmaceuticals INC. | $63.77 | 2024-2025 | Tlando |
| Merck Sharp & Dohme LLC | $63.36 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $56.62 | 2025 | |
| Chiesi USA, INC. | $56.55 | 2024-2025 | Mycapssa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.24 | 2019-2020 | |
| Pfizer INC. | $45.20 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $35.08 | 2019-2020 | |
| Halozyme INC | $34.74 | 2023 | |
| Medtronic Minimed, INC. | $33.94 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $33.31 | 2021-2022 | |
| Cequr Corporation | $33.22 | 2024 | Cequr Simplicity |
| Azurity Pharmaceuticals, INC. | $31.64 | 2023-2025 | Azmiro, Adthyza |
| Sequel Med Tech, LLC | $31.18 | 2025 | Twiist |
| Eusa Pharma (US) LLC | $31.13 | 2022 | |
| Exeltis, USA INC. | $30.19 | 2020-2023 | Slynd |
| Kyowa Kirin, INC. | $26.18 | 2025 | |
| Beta Bionics, INC. | $24.22 | 2024 | Ilet Bionic Pancreas |
| Esperion Therapeutics, INC. | $23.00 | 2023 | Nexletol |
| Acella Pharmaceuticals, LLC | $19.45 | 2025 | NP Thyroid 60 |
| Endo USA, INC. | $17.33 | 2024 | Aveed |
| Amryt Pharma Holdings LTD | $15.71 | 2023 | Mycapssa |
| Ascensia Diabetes Care US INC. | $14.36 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.08 | 2019 | |
| Horizon Therapeutics Plc | $13.08 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.21 | 2020 | |
| Endo Pharmaceuticals INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Derosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.